Canakinumab’s cardiovascular benefits linked with hsCRP cuts

Описание к видео Canakinumab’s cardiovascular benefits linked with hsCRP cuts

Targeting the anti-inflammatory drug canakinumab to cardiovascular disease patients with a robust response to a single dose may be an effective way to enhance the cost benefit of this novel treatment that is effective but also expensive, says Dr. Paul M. Ridker. #AHA

Комментарии

Информация по комментариям в разработке

Похожие видео